Bibliography Updates May 2020
Myriad RBM’s biomarker testing services and TruCulture product have been cited in over 1000 peer-reviewed research articles. As a CLIA-certified labo...
Serum Biomarker Signature Correlates With Cancer Drug Clearance and Predicts Overall Survival
In a study published in the Journal for ImmunoTherapy of Cancer December 2019 issue1, researchers demonstrate that a baseline serum biomarker signatur...
Inflammatory Markers Can Identify Non-Responders to Dendritic Vaccine
(Note: While the authors stated serum in the publication, the blood samples were collected in EDTA tubes. Thus, in the following summary, serum is cor...
Supplement: Who Gets Immunotherapy for Cancer?
Managing Patient Expectations Requires Better Biomarkers and Companion Diagnostics Read the full article at GEN News Improving Cancer Immunotherapy...
Monitoring IFN-gamma Responses in Serum
The Immunomodulatory Effects of Cancer Therapy on IFN-gamma Responses in the Periphery. (2017) Brunet LR, et al. SITC 2017 Annual Meeting; November 8...
IL-10 (AM0010) phase I trial offers novel mechanism for immune-oncology drugs in solid tumors
More commonly known as an inhibitory cytokine, high doses of interleukin 10 (IL-10) have been shown to lead to the activation and survival of antigen...
Researchers in this immuno-oncology trial used Myriad RBM’s services to measure serum biomarkers.
Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma The data presented in this paper shows baseline and on-treatment biomarkers...